Clinical trials: Intra-abdominal Infection
Candidemia, Other Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV
The objective of this study is to collect the safety and efficacy data of Eraxis IV (anidulafungin) 100 mg according to Korea Ministry of Food and Drug Safety regulations.
- Trial name
- NCT00802854
- Where
- 10 sites in South Korea
- Volunteers
- 244 people
- Sponsor
- Pfizer
Complicated Intra-abdominal Infection
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
This is a Phase 3, multicenter, prospective, randomized, double-blind, double dummy study of CXA-201 Intravenous (IV) infusions (1500mg q8h) and metronidazole (500mg q8h) versus meropenem (1000mg q8h)for the treatment of adults…
- Trial name
- NCT01445678
- Testing
- CXA-201 and metronidazole, Meropenem
- Where
- 61 sites in United States, Argentina and 13 more
- Volunteers
- 494 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Complicated Intra-abdominal Infection
Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections
A Phase 2, multicenter, prospective, randomized, double-blind study of CXA-101/ tazobactam (1000/500 mg q8h) and metronidazole (500 mg q8h) IV infusion vs.
- Trial name
- NCT01147640
- Testing
- CXA-101/ tazobactam and metronidazole
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 122 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Complicated Intra-abdominal Infections
Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).
This study will assess the safety , efficacy and pharmacokinetics of ceftazidime avibactam and metronidazole versus meropenem in paediatric population (from 3 months to less than 18 years of age )with complicated intra-abdominal…
- Trial name
- NCT02475733
- Testing
- Ceftazidime -avibactam, Meropenem, Metronidazole
- Where
- 35 sites in United States, Czechia and 8 more
- Volunteers
- 83 people
- Sponsor
- Pfizer
Intra-abdominal Infection, Complicated Intra-abdominal Infection
Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)
This is a Phase 3, multi-site, non-randomized, open-label study evaluating the safety and efficacy of MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg for the treatment of Complicated Intra-abdominal…
- Trial name
- NCT02739997
- Testing
- MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g), metronidazole 500 mg
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Complicated Intra-abdominal Infections
Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated intra-abdominal infections as compared to a comparator group.
- Trial name
- NCT00752219
- Testing
- ceftazidime/NXL104 + metronidazole, meropenem
- Where
- 45 sites in United States, Bulgaria and 6 more
- Volunteers
- 204 people
- Sponsor
- Pfizer
Intra-abdominal Infection
A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
This is a comparative study of the efficacy and safety of tigecycline to imipenem/cilastatin in hospitalized patients with a complicated intra-abdominal infection.
- Trial name
- NCT01721408
- Testing
- Tigecycline, Imipenem/cilastatin
- Where
- 47 sites in China
- Volunteers
- 470 people
- Sponsor
- Pfizer
Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
To Evaluate the Effects of Ceftazidime-Avibactam and Best Available Therapy in patients with complicated urinary tract infections and complicated intra-abdominal infections.
- Trial name
- NCT01644643
- Testing
- Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole
- Where
- 43 sites in United States, Argentina and 16 more
- Volunteers
- 345 people
- Sponsor
- Pfizer
Complicated Intra-Abdominal Infection
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
- Trial name
- NCT01499290
- Testing
- CAZ-AVI, Metronidazole, Meropenem
- Where
- 56 sites in United States, Argentina and 18 more
- Volunteers
- 493 people
- Sponsor
- Pfizer
Complicated Intra-abdominal Infection
Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
- Trial name
- RECLAIM3 (NCT01726023)
- Testing
- Ceftazidime-avibactam, metronidazole, Meropenem
- Where
- 30 sites in China, South Korea and 1 more
- Volunteers
- 486 people
- Sponsor
- Pfizer
Abscess, Intra-Abdominal, Abdominal Abscess
A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
The purpose of the study is to evaluate the safety and tolerability of doripenem compared with meropenem in children hospitalized with complicated intra-abdominal infections.
- Conditions
- Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute, Abdominal Pain
- Trial name
- NCT01110382
- Testing
- Doripenem, Meropenem, Amoxicillin/clavulanate potassium
- Where
- 19 sites in United States, Argentina and 6 more
- Volunteers
- 41 people
- Sponsor
- Janssen Research & Development, LLC
Intra-abdominal Infections
A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection
The purpose of this study is to evaluate the clinical efficacy and safety in Japanese adult subjects with Intra-abdominal/Pelvic infections receiving Metronidazole IV 1,500-2,000 mg/day in combination with ceftriaxone sodium.
- Trial name
- NCT01473836
- Testing
- Metronidazole, Ceftriaxone sodium
- Where
- 15 sites in Japan
- Volunteers
- 38 people
- Sponsor
- Pfizer
Infection, Cross Infection
A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections
The purpose of this study is to assess the safety and efficacy of doripenem in participants with nosocomial pneumonia (inflammation of the lungs in which the lungs become heavy; pneumonia occurring at least 48 hours after…
- Conditions
- Infection, Cross Infection, Bacterial Infections, Pneumonia, Ventilator-Associated
- Trial name
- NCT00965848
- Testing
- Doripenem
- Where
- 8 sites in Thailand
- Volunteers
- 270 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Appendicitis, Cholecystitis
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy through the test-of-cure assessment.
- Conditions
- Appendicitis, Cholecystitis, Diverticulitis, Intra-Abdominal Abscess
- Trial name
- NCT00230971
- Testing
- tigecycline, ceftriaxone plus metronidazole
- Where
- 68 sites in Australia, China and 17 more
- Volunteers
- 473 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Bacterial Infections, Intra-Abdominal Infection
Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age
To determine the pharmacokinetic profile and to evaluate the safety and tolerability of ascending multiple doses of tigecycline in patients aged 8 to 11 years with selected serious infections; complicated intra-abdominal…
- Conditions
- Bacterial Infections, Intra-Abdominal Infection, Pneumonia, Bacterial, Skin Diseases, Bacterial
- Trial name
- NCT00488345
- Testing
- Tygacil
- Where
- 36 sites in United States, Belgium and 4 more
- Volunteers
- 59 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Complicated Intra-Abdominal Infection
Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
The objective of this study is to estimate the costs of empiric antibiotic therapy and hospitalization costs for patients with a complicated intra-abdominal infection, and to assess the impact of treatment failure of initial…
- Trial name
- NCT00929643
- Testing
- no intervention
- Where
- 13 sites in Greece
- Volunteers
- 203 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Intra-Abdominal Infections, Skin Disease, Infectious
Post-Authorization Study Evaluating Safety Of Tigecycline
This is a study to evaluate the safety of tigecycline in patients with complicated intra-abdominal infections (cIAI) and complicated skin and soft tissue infections (cSSTI) under real practice in the usual hospital setting and…
- Conditions
- Intra-Abdominal Infections, Skin Disease, Infectious, Soft Tissues Infections
- Trial name
- HORUS (NCT00827541)
- Testing
- Tigecycline
- Volunteers
- 115 people
- Sponsor
- Pfizer
Complicated Skin and Skin Structure Infections, Complicated Intra-abdominal Infections
Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)
The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.
- Trial name
- NCT00683332
- Testing
- Tigecycline (Tygacil)
- Where
- Philippines
- Volunteers
- 621 people
- Sponsor
- Pfizer